Subscribe Now
  • Home
  • Latest
    • News
    • North America
    • Europe
    • Asia
    • Middle East
    • Global
  • Coins2Day 500
    • Coins2Day 500 U.S.
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
  • Finance
    • Economy
    • Banking
    • Personal Finance
    • Investing
    • Real Estate
    • Energy
    • Crypto
  • Tech
    • Big Tech
    • Startups & Venture
    • AI
    • Innovation
    • Cybersecurity
  • Leadership
    • Future Of Work
    • Success
    • C-Suite
    • Workplace Culture
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Health
    • Travel & Leisure
    • Education
  • Rankings
    • Great Place To Work
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Press Releases
    • Video
    • Podcasts
  • Home
  • Latest
    • Latest
    • News
    • North America
    • Europe
    • Asia
    • Middle East
    • Global
  • Coins2Day 500
    • Coins2Day 500
    • Coins2Day 500 U.S.
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
  • Finance
    • Finance
    • Economy
    • Banking
    • Personal Finance
    • Investing
    • Real Estate
    • Energy
    • Crypto
  • Tech
    • Tech
    • Big Tech
    • Startups & Venture
    • AI
    • Innovation
    • Cybersecurity
  • Leadership
    • Leadership
    • Future Of Work
    • Success
    • C-Suite
    • Workplace Culture
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Health
    • Travel & Leisure
    • Education
  • Rankings
    • Rankings
    • Great Place To Work
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Press Releases
    • Video
    • Podcasts
  1. home
  1. home
  2. Merck

Merck

Page 6 of 9

donald trump resigns council charlottesville
Leadership

Merck CEO Quits Trump Council Over President’s Charlottesville Response

By Julia Zorthian
August 14, 2017
Cyber ‘Worm’ Attack Hits Global Corporate Earnings
Tech

Cyber ‘Worm’ Attack Hits Global Corporate Earnings

By Reuters
August 2, 2017
Petya ransomware cyber attack
Tech

Ransomware Cost Surpasses $25 Million Mark

By Barb Darrow
July 27, 2017
Johnson & Johnson’s Pricey Best-Selling Drug Will Have to Face a 35% Cheaper Rival
Health

Johnson & Johnson’s Pricey Best-Selling Drug Will Have to Face a 35% Cheaper Rival

By Sy Mukherjee
July 24, 2017
Tuesday’s Massive Cyber Attacks Hit U.S. Drug Giant Merck
Health

Tuesday’s Massive Cyber Attacks Hit U.S. Drug Giant Merck

By Sy Mukherjee
June 27, 2017
These Are the Known Targets in the Petya Ransomware Attack So Far
Tech

These Are the Known Targets in the Petya Ransomware Attack So Far

By Reuters
June 27, 2017
Forbes Under 30 Summit
Health

This 31-Year-Old Just Launched His 5th Biotech Company With a Boost From Merck

By Sy Mukherjee
June 6, 2017
BRITAIN-PHARMA-BUSINESS-ASTRAZENECA
Finance

Why Drug Giant AstraZeneca’s Stock Soared More Than 9% on Friday

By Sy Mukherjee
May 12, 2017
Why Merck’s Keytruda Just Became a Lung Cancer Game Changer
Health

Why Merck’s Keytruda Just Became a Lung Cancer Game Changer

By Sy Mukherjee
May 11, 2017
FDA Approves New Drug That Could Take a Slice Out of Johnson & Johnson’s Best Seller
Health

FDA Approves New Drug That Could Take a Slice Out of Johnson & Johnson’s Best Seller

By Sy Mukherjee
April 24, 2017
Another Failure in Alzheimer’s. Another Shrug.
Health

Another Failure in Alzheimer’s. Another Shrug.

By Clifton Leaf
February 15, 2017
Pharmaceutical Production Inside Merck KGaA Health Care Laboratory
Health

This Pharma Giant Just Pulled Back the Curtain On Its Drug Price Hikes

By Sy Mukherjee
January 29, 2017
Trading On The Floor Of The NYSE As U.S. Stocks Decline With Banks, Health Shares Lower
Health

Why These Two Pharma Stocks Are Having Drastically Different Days

By Sy Mukherjee
January 20, 2017
The logo of German pharmaceuticals company Merck is seen in front of the company's headquarters in Darmstadt
Tech

Palantir’s Bet on Big Pharma

By Michal Lev-Ram
January 12, 2017
These 3 Ugly Patent Battles Could Rock Biopharma’s 2017
Health

These 3 Ugly Patent Battles Could Rock Biopharma’s 2017

By Sy Mukherjee
January 7, 2017

Most Popular

  • AI
    Elon Musk says that in 10 to 20 years, work will be optional and money will be irrelevant thanks to AI and robotics
    By Sasha Rogelberg
  • Success
    Despite his $2.6 billion net worth, MrBeast says he’s having to borrow cash and doesn’t even have enough money in his...
    By Emma Burleigh
  • Politics
    The U.S. Supreme Court could throw a wrench into Trump’s plan to take Greenland as soon as Tuesday
    By Jim Edwards
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • MPW
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms of Use
  • Single Issues for Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work at Coins2Day
  • Diversity and Inclusion
  • Terms and Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.